Search

Displaying results 1661 - 1670 of 6835 in total
  1. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [A261596] When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria

  2. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    to be approved for this specific patient population. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  3. Drug

    Polyvinyl alcohol

    go.drugbank.com/drugs/DB11060
    Approved

    Polyvinyl alcohol is found in ophthalmic solutions as a lubricant to prevent irritation or to relieve dryness of the eyes [L2826]. … Polyvinyl alcohol is a water-soluble synthetic polymer obtained by polymerization of vinyl alcohol.

  4. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    [A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.

  6. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration.

  7. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation … and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.

  8. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovas...

    Mixtures: TL-Care DHA, TODAVİT IM/IV ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 4 ADET
  9. Drug

    Melatonin

    go.drugbank.com/drugs/DB01065
    ApprovedInvestigationalNutraceuticalVet approved

    ) but outside the blood-brain barrier. … In mammals, melatonin is produced by the pineal gland.

    International brands: Mela-T
  10. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    due to non-selective steroidal activities [A275513, A275514]. … On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].